Stereotactic radiation (surgical) treatments such as gamma knife, radio wave knife, and proton knife are not really open surgery and are generally considered to be non-invasive treatments, which must be good if they can control the growth of glioma. The reality is: No surgery without pathological diagnosis can theoretically make the diagnosis of a solid glioma. The diffuse growth pattern of gliomas dictates that radiosurgical treatments such as gamma knife are not appropriate for the treatment of newly diagnosed gliomas. Gliomas grow diffusely without clear tumor cytologic boundaries. The highest density of tumor cells is found within the tumor, and the peritumor becomes less dense as the distance becomes farther away, which is a migratory process with normal brain tissue, and the distance of this migration is not yet clear. Therefore, the surgical guidelines recommend glioma surgery as maximum safe resection, that is, the maximum resection with safety, and the more cut the better. Since the tumor cytologic boundary is not well determined, surgeons no longer obsess about where the tumor cell boundary is, but locate the functional area around the tumor and resect the tumor according to the functional boundary, that is, resect the tumor directly to the functional boundary, so that maximum safe resection is achieved. Stereotactic radiation (surgical) treatment, such as gamma knife, radio wave knife, proton knife, etc., uses external ionizing radiation beams (rays, X-rays or charged particle beams) and precise positioning of stereotactic system to focus high energy radiation on a local target area and destroy all tissues in the area to achieve the effect similar to surgical operation. Generally, the target area is less than 3-5 cm, which shows that stereotactic radiosurgery is a local treatment and cannot meet the requirement of maximum safe tumor removal for glioma. At present, stereotactic radiosurgery (surgery) such as gamma knife, radio wave knife, and proton knife are mainly used for local small volume recurrent glioma for re-course radiation therapy, and are not used as the first choice radiation therapy option for glioma.